Pfizer Inc. (NYSE: PFE) Q2 2021 Earnings call dated Jul. 28, 2021 Corporate Participants: Christopher Stevo — Senior Vice President, Chief Investor Relations Officer Albert
Pfizer Inc. (PFE) Q2 2021 Earnings Call
Categories
pharmaceuticals
Infographic: How Pfizer (PFE) performed in Q2 2021
Pfizer Inc. (NYSE: PFE) reported second quarter 2021 earnings results today. Total revenue increased 92% year-over-year to $19 billion. GAAP net income
IPO Alert: What to look for when Ocean Biomedical goes public
After tech start-ups, the biotechnology industry is keeping the IPO market busy nowadays. It is estimated that Wall Street is headed for
Abbott Laboratories ease past street targets: Infographic
Abbott Laboratories (NYSE: ABT) reported second-quarter 2021 financial results before the regular market hours on Thursday. The pharmaceutical giant reported Q2 sales
Biogen (BIIB) Earnings Infographic: Q2 profit, revenue drop but top estimates
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The results, however, came in
Johnson & Johnson beats in Q2; raises FY guidance
Johnson & Johnson (NYSE: JNJ) reported second-quarter 2021 financial results before the regular market hours on Wednesday. The pharmaceutical giant reported Q2
Absci IPO: Here’s all you need to know about bioengineering firm’s Nasdaq listing
Wall Street is probably going through the busiest phase since the recession, in terms of the number of businesses seeking to go
IPO News: Should you invest in Sight Sciences’ initial public offering?
The continuing stock market rally, at a time when the pandemic-hit economy is struggling to regain strength, has set off an IPO
Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?
The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with the technology and pharma
Context Therapeutics: Another clinical-stage oncology research firm to go public soon
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development
IPO News: What to look for when Elevation Oncology makes its Wall Street debut
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly
Trxade Health Inc. (NASDAQ: MEDS) Q2 2021 Research Summary
Trxade Health Inc. (NASDAQ: MEDS), a health services IT company, plays a key role in ensuring the availability of healthcare services at
Is Merck (MRK) stock still a buy after losing the vaccine race?
After bringing the global economy to a grinding halt, the coronavirus pandemic is subsiding in most regions, thanks to the mass production
LLY Stock: Is Eli Lilly a good bet in COVID-challenged healthcare market?
For pharmaceutical companies, 2020 was a busy year when the healthcare sector went into overdrive to deal with the challenges posed by
SmileDirectClub (SDC) bets on rapid telemedicine-adoption to drive growth
The adoption of telemedicine accelerated in recent months, especially after the pandemic-related shelter-in-place orders came into effect. The trend will likely continue
SmileDirectClub (SDC) Q1 Report: Net loss narrows but misses estimates
Digital healthcare firm SmileDirectClub Inc. (NASDAQ: SDC) reported a narrower net loss for the first quarter of 2021 amid modest revenue growth.
Pfizer, Inc. (PFE) Q1 2021 Earnings Call Transcript
Pfizer, Inc. (NYSE: PFE) Q1 2021 earnings call dated May. 04, 2021 Corporate Participants: Charles E. Triano -- Senior Vice President, Investor Relations Albert
Pfizer (PFE) reports Q1 EPS of 93 cents: Infographic
Pfizer (NYSE: PFE) reported first-quarter 2021 financial results ahead of the regular market hours on Tuesday. The pharmaceutical giant reported Q1 revenue
AbbVie (ABBV) Stock: Here’s what you need to know before investing
AbbVie Inc. (NYSE: ABBV) has long been fighting to delay the entry of generic alternatives to Humira, the pharma giant's flagship product
Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q1 2021 earnings call dated Apr. 29, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations